Contact
Research areas that we serve nationally
Brandi is a results driven leader with extensive experience in the digital and healthcare industry. Her proven track record with strategic partnerships, commercial and business development teams’ position Elixia for strategic growth, revenue obtainment, and partnership expansion.
Mike is a seasoned leader with over 13 years of experience in Patient Recruitment, known for his results-oriented approach. He has successfully led teams in Finance, Operations, and Commercial sectors, demonstrating his ability to drive performance and achieve strategic goals.
Currently, Mike serves as the President of Patient Recruitment (CSSi), where he continues to leverage his leadership skills to enhance organizational growth and efficiency.
Throughout his career, Mike has held prominent positions at Acurian, AES, and PPD. At Acurian, he honed his expertise in patient recruitment strategies. His tenure at AES and PPD further solidified his reputation as a dynamic leader capable of navigating complex business environments. Mike’s commitment to excellence and innovation has consistently delivered outstanding results across all facets of his career.
Sarah Petrucci brings a wealth of financial and accounting knowledge to Elixia. With a career spanning 20 years, distinguished by leadership roles at Thermo Fisher Scientific/PPD and PwC, Sarah brings unparalleled financial expertise to our leadership team. Her exceptional track record in SEC reporting, public offerings, investment valuation, and business combinations positions her as an indispensable asset to our executive team.
Sarah graduated from the Kenan-Flagler Business School at the University of North Carolina at Chapel with both a Bachelor of Science in Business Administration degree and a Master of Accounting degree. Sarah is a CPA licensed in North Carolina, having spent 13 years in public accounting before transitioning into the life sciences industry.
At Elixia, Sarah is the financial veteran steering our ambitious organic and inorganic growth initiatives. Her strategic oversight ensures that all critical financial metrics are meticulously monitored, enabling Elixia to not only meet but exceed our expansion goals. Under her leadership, we are poised to solidify our standing as the world’s leading clinical trials company.
With Sarah at the financial helm, Elixia is equipped to navigate the complexities of rapid growth and achieve unparalleled financial success, ensuring our continued ascendancy in the global clinical trials landscape.
Dustin Owen is the Chief Executive Officer of Elixia, bringing with him a distinguished background in the clinical research and biopharmaceutical industries. With a career marked by leadership roles at some of the world’s top companies, Dustin is poised to drive Elixia to new heights.
Before joining Elixia, Dustin served as Senior Vice President and General Manager of Accelerated Enrollment Solutions (AES) at Thermo Fisher Scientific/PPD. There he was responsible for more than 160 clinical research sites across 15 countries, managing a workforce of 2,000 employees. His extensive experience includes overseeing operations in diverse global markets, ensuring high standards of clinical trial execution and patient recruitment.
Dustin’s previous roles include Head of Asia Pacific Clinical Operations and Vice President of Strategic Laboratory Operations at Thermo Fisher/PPD, as well as key positions at LabCorp, Biogen, and Manhattan Associates. Since joining PPD in 2013, he consistently demonstrated his ability to lead large-scale operations and drive organizational growth.
At Elixia, Dustin focuses on leveraging his expertise to enhance the company’s growth and operational efficiency. His vision encompasses ensuring the delivery of top-tier clinical research services, expanding our global reach, and further fortifying Elixia’s leadership in therapeutic specialty areas. He is committed to fostering an inclusive, patient-centric approach that addresses significant unmet medical needs through innovative research.
Dustin’s strategic leadership is expected to propel Elixia into a new era of growth and excellence. His appointment aligns with Elixia’s mission to advance scientific research and improve patient outcomes on a global scale.
Dr. Harry Alcorn is an integral part of the Elixia team, adding a rich tapestry of both scientific acumen and operational insight borne of over two decades of industry experience. Harry’s unique capability to seamlessly integrate operational strategy with a scientific approach is key to maintaining Elixia’s reputation as a forward-thinking, innovative, and reproducible trial management organization.
Serving as the head of operations in the Early Phase Clinical Trials Division of Elixia, Harry’s leadership is essential in driving our unique position as the only niche-focused clinical trials company conducting Phase I-IV trials. His profound expertise is instrumental in maintaining the company’s commitment to excellence, reliability, and innovation.
Harry joined Elixia in 2023, bringing with him a mission to create a comprehensive ecosystem of clinical trial services offered to the industry. Guided by this vision, he has been at the helm of the Phase I Division, overseeing a range of initiatives and ensuring the delivery of top-tier services.
Under Harry’s stewardship, Elixia continues to disrupt the clinical trial landscape, setting new standards and paving the way for future advancements. His unwavering dedication to improving patient outcomes, coupled with a deep commitment to scientific rigor, perfectly mirrors Elixia’s ethos.
Harry’s robust experience, passion for innovation, and strategic leadership are pivotal in Elixia’s pursuit to revolutionize the way clinical trials are conducted. His work is not just a testament to his individual expertise, but also a reflection of the collective drive of Elixia to make a profound impact on the lives of patients across the globe.
In his role of Chief Operating Officer for Elixia, Jim Crissy brings extensive industry and clinical trial management experience to the executive team. He provides strategic direction and operational oversight to a diverse and unique system of logistics that reflect the disruptive nature of Elixia’s forward approach to clinical trials.
Prior to joining Elixia in January 2019, Crissy served as COO of a company specialized in conducting Phase I-IV End Stage Renal Disease Trials. During this time, Crissy organized and managed a team that became well recognized as one of the top performing units on the East Coast in the Nephrology space. With over 18 years of experience operating in clinical trial management, Crissy has garnered a unique understanding of the evolution of clinical trial operating models – which accelerates Elixia’s ability to not only stay innovative and agile in the execution of novel workflows and trial management, but continue to challenge traditional trial management best practices.
Neal Patel is a healthcare and biotechnology entrepreneur in both the Pharmaceutical and Biomedical marketplace. Neal founded his first clinical diagnostics company at the age of 23. Armed with a passion for enhancing the accessibility to healthcare for disparate communities, he launched a private R&D Laboratory, responsible for engineering disruptive, cost-effective diagnostic tests focused on several cardiovascular indications. Over the next 3 years, Neal had developed one of the largest dedicated Cardiology networks for molecular diagnostics and clinical research on the east coast.
Maximizing the power of strategic foresight, Neal began developing a crossover network between Cardiology and Nephrology and in 2018 Elixia was born. Elixia’s Cardio-Renal Network became the largest dedicated footprint for clinical trials in the Southeast and is currently the fastest growing clinical trials footprint within the Cardio-Renal specialty in North America.
Under his leadership, Elixia’s total enterprise value has more than quadrupled, the number of employees tripled and the company has received numerous accolades for its work across several therapeutic focuses. Elixia’s mission is to redevelop the landscape in which clinical trials have been conducted over the last 50 years and deliver a new environment where Clinical Trial Rollout, Conduct, and Management can occur at breakneck pace with an unparalleled level of quality.